SEC Form 4 · accession 0001209191-15-034122
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory T Went
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Apr 10, 2015
Accepted (ET)
Apr 14, 2015 · 7:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 10, 2015 | M | 1,000 | $1.875 | A | 11,008 | D | |
| Common StockF2,F1 | Apr 10, 2015 | S | 900 | $18.0889 | D | 10,108 | D | |
| Common StockF1 | Apr 10, 2015 | S | 100 | $19.00 | D | 10,008 | D | |
| Common StockF3,F1 | Apr 10, 2015 | S | 3,077 | $18.1595 | D | 402,903 | I | Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11 |
| Common StockF4,F1 | Apr 10, 2015 | S | 500 | $19.07 | D | 402,403 | I | Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11 |
| Common StockF1 | Apr 14, 2015 | M | 80 | $1.875 | A | 10,088 | D | |
| Common StockF1 | Apr 14, 2015 | S | 80 | $18.00 | D | 10,008 | D | |
| Common StockF1 | Apr 14, 2015 | S | 10,000 | $1.875 | A | 20,008 | D | |
| Common StockF1 | Apr 14, 2015 | S | 100 | $18.00 | D | 402,303 | I | Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11 |
| Common Stock | holding | — | — | — | 6,666 | I | Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act | |
| Common Stock | holding | — | — | — | 6,666 | I | Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors Act | |
| Common Stock | holding | — | — | — | 80,000 | I | Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went | |
| Common Stock | holding | — | — | — | 80,000 | I | Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Cora Margaret Went |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $1.875 | Apr 10, 2015 | M | 1,000 | D | — | Sep 12, 2016 | Common Stock | 1,000 | 230,080 | D |
| Stock Option (Right to Buy)F5 | $1.875 | Apr 14, 2015 | M | 80 | D | — | Sep 12, 2016 | Common Stock | 80 | 230,000 | D |
| Stock Option (Right to Buy)F5 | $1.875 | Apr 14, 2015 | M | 10,000 | D | — | Sep 12, 2016 | Common Stock | 10,000 | 220,000 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $18.00 to $18.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $18.00 to $18.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $19.00 to $19.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This option is fully vested and exercisable.